Back to search results

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Liver Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic, Phoenix, Arizona, United States

    Contact: Study coordinator (Mitesh J. Borad, MD) · 855-776-0015

  • Mayo Clinic, Jacksonville, Florida, United States

    Contact: Study coordinator (Hani M. Babiker, MD) · 855-776-0015

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Richard Kim, MD)
    Contact: Study coordinator (O'Neke Nickle) · O'Neke.Nickle@moffitt.org

  • Mayo Clinic, Rochester, Minnesota, United States

    Contact: Study coordinator (Nguyen H. Tran, MD) · 855-776-0015

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Max Sung, MD) · GICancerClinicalResearch@mssm.edu

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Sunyoung Lee, MD) · GIClinicalTrials@mdanderson.org

  • The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

  • Beijing Tsinghua Changgung Hospital, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Gong Li, Doctor)
    Contact: Principal Investigator (Gong Li, Doctor)

  • The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital, Chongqing, Chongqing Municipality, China

    Contact: Study coordinator (Dewei Li, Doctor)
    Contact: Principal Investigator (Dewei Li, Doctor)
    Contact: Principal Investigator (Yongsheng Li, Doctor)

  • Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China

  • Sun Yat Sen Memorial Hospital, Guangzhou, Guangdong, China

  • Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China

  • Weifang People's Hospital, Weifang, Hebei, China

  • Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China

    Contact: Study coordinator (Yuxian Bai, Doctor)
    Contact: Principal Investigator (Yuxian Bai, Doctor)

  • First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

  • Henan Cancer Hospital, Zhengzhou, Henan, China

  • Hubei Cancer Hospital, Wuhan, Hubei, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China

    Contact: Study coordinator (Xiaoping Chen, Doctor)
    Contact: Principal Investigator (Xiaoping Chen, Doctor)

  • Hunan Cancer Hospital, Changsha, Hunan, China

  • Hunan Provincial People's Hospital, Changsha, Hunan, China

  • Suzhou University Affiliated Second Hospital, Suzhou, Jiangsu, China

  • Tonghua Central Hospital, Tonghua, Jilin, China

  • Shengjing Hospital of China medical university, Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China

  • Jinan Central Hospital, Jinan, Shandong, China

  • Linyi Cancer Hospital, Linyi, Shandong, China

  • The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Shanxi, China

  • Mianyang Central Hospital, Mianyang, Sichuan, China

    Contact: Study coordinator (Xiaobo Du, Doctor)
    Contact: Principal Investigator (Xiaobo Du, Doctor)

  • Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China

  • National Cheng Kung University Hospitals, Tainan, Taiwan

  • Nation Taiwan University Hospital, Taipei, Taiwan

Study leads

  • Xiaoping Chen, Doctor

    Principal Investigator

    Tongji Hospital

View source on ClinicalTrials.gov(opens in a new tab)